Plasma S100A8 and S100A9 Are Strong Prognostic Factors for Hepatitis B Virus-Related Acute-on-Chronic Liver Failure

Figure 4

Prognostic performance of the ACLF prognostic scoring systems. (a) Plasma S100A8 (b) and S100A9 distribution of HBV-ACLF patients survive or no survive at 28 or 90 days. (c) ROC curves of prognostic models in predicting 28-day mortality (d) and 90-day mortality in HBV-ACLF patients. (e) Probability of transplant-free survival at 28/90-day on the basis of the CLIF-C OF-S100s cutoff value in ACLF patients. The log-rank test was not to compare the Kaplan–Meier curves. Horizontal lines and error bars represent media ±95% confidence interval (CI).

(a)

(b)

(c)

(d)

(e)